PT  - JOURNAL ARTICLE
AU  - Vedat Hamuryudan
AU  - Gulen Hatemi
AU  - Koray Tascilar
AU  - Sebahattin Yurdakul
AU  - Cem Mat
AU  - Yilmaz Ozyazgan
AU  - Emire Seyahi
AU  - Serdal Ugurlu
AU  - Hasan Yazici
TI  - Colchicine in Behçet Syndrome: A Longterm Survey of Patients in a Controlled Trial
AID  - 10.3899/jrheum.130847
DP  - 2014 Apr 01
TA  - The Journal of Rheumatology
PG  - 735--738
VI  - 41
IP  - 4
4099  - http://www.jrheum.org/content/41/4/735.short
4100  - http://www.jrheum.org/content/41/4/735.full
SO  - J Rheumatol2014 Apr 01; 41
AB  - Objective. To test the hypothesis that colchicine use during early disease decreases immunosuppressive use in Behçet syndrome (BS) in the long term. Methods. Patients with BS who participated in a double-blind, placebo-controlled trial of colchicine 16.6 ± 1.1 years ago were evaluated for immunosuppressive use during the posttrial period. Results. We could contact 90/116 patients; 28 (31%) received immunosuppressives during the posttrial period, 14 being from the colchicine arm. Posttrial colchicine use and cumulative duration were similar between patients who received immunosuppressives and those who did not. Conclusion. Continuous use of colchicine, even when initiated at an early disease stage, does not seem to decrease the use of immunosuppressives in the long term.